跳至主要内容
临床试验/JPRN-UMIN000008947
JPRN-UMIN000008947已完成2 期

Phase II study of bevacizumab and irinotecan plus alternate-day S-1 as second-line therapy in patients with metastatic colorectal cancer. - AIRS study

Epidemiological and Clinical research Information Network (ECRIN)0 个研究点目标入组 40 人开始时间: 2012年9月19日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)History of serious drug hypersensitivity 2)Active infections 3) Serious complications (interstitial pneumonitis, pulmonary fibrosis, renal failure, liver dysfunction, poorly controlled DM, poorly controlled hypertension) 4) Distinctly abnormal ECG or cardiovascular disease (heart failure, myocardial infarction, angina) 5) Massive pleural effusion or ascites 6) Ongoing treatment with Flucytosine, Phenytoin or Warfarin potassium 7) Synchronous or metachronous malignancy except carcinoma in situ 8) Prior radiotherapy 9) Diarrhea 10) Active hepatitis type HBs positive 11) History of thromboembolism, brain infarction, pulmonary infarction and interstitial pneumonitis 12) GI perforation or hemorrhage 13) Peritoneal metastasis 14) Brain metastasis 15)Pregnant or possibly pregnant women 16) Men who want get partner pregnant. 17) Other conditions not suitable for this study

研究者

发起方
Epidemiological and Clinical research Information Network (ECRIN)

相似试验